论文部分内容阅读
目的探讨急性白血病患者血清及脑脊液基质细胞衍生因子1α(SDF-1α)的表达水平及临床意义。方法采用酶联免疫吸附法(ELISA)检测化疗前和经标准方案化疗2个疗程后的26例急性白血病患者及14例同期普通外科入院患者血清及脑脊液中SDF-1的水平,并进行对照研究。结果初诊未治时急性白血病患者组血清及脑脊液中SDF-1α浓度明显高于对照组,差异有统计学意义(P<0.01);急性淋巴细胞性白血病组明显高于急性髓系白血病组,差异有统计学意义(P<0.01)。急性白血病患者经标准方案化疗2个疗程后,血清及脑脊液中SDF-1α浓度明显降低,差异有统计学意义(P<0.01);未缓解患者血清及脑脊液中SDF-1α浓度明显高于完全缓解的患者,差异有统计学意义(P<0.01);化疗前患者中枢神经系统白血病(CNSL)组、非中枢神经系统白血病(N-CNSL)组血清及脑脊液中SDF-1α浓度明显高于对照组,且CNSL患者组明显高于N-CNSL患者,差异均有统计学意义(P<0.01)。结论 SDF-1α可以作为急性白血病特别是中枢神经系统白血病患者的一种检测病情变化的指标,用于判断病情发展及预后。
Objective To investigate the expression and clinical significance of serum and cerebrospinal fluid stromal cell-derived factor 1α (SDF-1α) in patients with acute leukemia. Methods The levels of serum and cerebrospinal fluid of 26 acute leukemia patients and 14 normal surgical admissions patients before and after standard regimen chemotherapy were detected by enzyme-linked immunosorbent assay (ELISA). The control group . Results The serum level of SDF-1α in serum and cerebrospinal fluid of newly diagnosed untreated acute leukemia patients was significantly higher than that of the control group (P <0.01); acute lymphoblastic leukemia group was significantly higher than that of acute myeloid leukemia group There was statistical significance (P <0.01). After two courses of standard chemotherapy, the concentration of SDF-1α in serum and cerebrospinal fluid of patients with acute leukemia was significantly lower (P <0.01). The concentration of SDF-1α in serum and cerebrospinal fluid of patients with acute leukemia was significantly higher than that of complete remission (P <0.01). The concentrations of SDF-1α in serum and cerebrospinal fluid of patients with central nervous system leukemia (CNSL) and non-central nervous system leukemia (N-CNSL) before chemotherapy were significantly higher than those of the control group , And CNSL patients was significantly higher than N-CNSL patients, the differences were statistically significant (P <0.01). Conclusion SDF-1α can be used as an indicator of changes in patients with acute leukemia, especially in patients with central nervous system leukemia, to determine the progression of disease and its prognosis.